BR112023023794A2 - Sequências de proteínas e ácidos nucleicos para vacinas covid-19 - Google Patents

Sequências de proteínas e ácidos nucleicos para vacinas covid-19

Info

Publication number
BR112023023794A2
BR112023023794A2 BR112023023794A BR112023023794A BR112023023794A2 BR 112023023794 A2 BR112023023794 A2 BR 112023023794A2 BR 112023023794 A BR112023023794 A BR 112023023794A BR 112023023794 A BR112023023794 A BR 112023023794A BR 112023023794 A2 BR112023023794 A2 BR 112023023794A2
Authority
BR
Brazil
Prior art keywords
covid
protein
vaccines
nucleic acid
acid sequences
Prior art date
Application number
BR112023023794A
Other languages
English (en)
Portuguese (pt)
Inventor
Rosario Beccari Andrea
Annamaria Cimini
Carmine Talarico
Maria Ester Mauri Elisabetta
Franca Cattani
Marcello Allegretti
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of BR112023023794A2 publication Critical patent/BR112023023794A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023023794A 2021-05-14 2022-05-16 Sequências de proteínas e ácidos nucleicos para vacinas covid-19 BR112023023794A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21173941.2A EP4088738A1 (en) 2021-05-14 2021-05-14 Novel protein and nucleic acid sequences for covid-19 vaccines
PCT/EP2022/063214 WO2022238585A1 (en) 2021-05-14 2022-05-16 Novel protein and nucleic acid sequences for covid-19 vaccines

Publications (1)

Publication Number Publication Date
BR112023023794A2 true BR112023023794A2 (pt) 2024-03-12

Family

ID=75936784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023794A BR112023023794A2 (pt) 2021-05-14 2022-05-16 Sequências de proteínas e ácidos nucleicos para vacinas covid-19

Country Status (10)

Country Link
US (1) US20250282831A1 (enExample)
EP (2) EP4088738A1 (enExample)
JP (1) JP2024517345A (enExample)
CN (1) CN117915945A (enExample)
AU (1) AU2022272659A1 (enExample)
BR (1) BR112023023794A2 (enExample)
CA (1) CA3219586A1 (enExample)
IL (1) IL308407A (enExample)
WO (1) WO2022238585A1 (enExample)
ZA (1) ZA202311432B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245344A1 (zh) * 2023-05-30 2024-12-05 石药集团巨石生物制药有限公司 预防新型冠状病毒奥密克戎突变株的mRNA疫苗

Also Published As

Publication number Publication date
EP4088738A1 (en) 2022-11-16
CN117915945A (zh) 2024-04-19
CA3219586A1 (en) 2022-11-17
AU2022272659A1 (en) 2023-11-23
JP2024517345A (ja) 2024-04-19
WO2022238585A1 (en) 2022-11-17
AU2022272659A9 (en) 2023-11-30
ZA202311432B (en) 2025-04-30
US20250282831A1 (en) 2025-09-11
IL308407A (en) 2024-01-01
EP4337250A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR122021025194A8 (pt) Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
BR112019011642A2 (pt) sistema e métodos para o biocontrole de patógenos de planta
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
MX2017012485A (es) Dominios dise?ados con repeticiones de anquirina con especificidad de union para la seroalbumina.
AR109680A1 (es) Proteínas recombinantes y sus usos
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
BR112015013004A2 (pt) molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo
BR112018011059A2 (pt) synp161, um promotor para a expressão específica de genes em fotoreceptores de haste
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
MX2018001126A (es) Oligonucleotidos terapeuticos.
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
BR112018068890A2 (pt) dna polimerases marinhas
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
BR112019003950A2 (pt) identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma
BR112019007408A2 (pt) vacina de dna tolerogênica
CO2018006298A2 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
BR112023012293A2 (pt) Composições de protoparvovírus e tetraparvovírus e métodos para terapia gênica
MX2022001626A (es) Composiciones biofarmaceuticas y procedimientos conexos.